# HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

> **NCT01576341** · PHASE3 · COMPLETED · sponsor: **Sandoz** · enrollment: 417 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** HX575 epoetin alfa (Sandoz)

## Key facts

- **NCT ID:** NCT01576341
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-10
- **Final completion:** 2015-06
- **Target enrollment:** 417 (ACTUAL)
- **Last updated:** 2017-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576341, "HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01576341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*